Abstract
The purpose of this study was to clarify the factors related to silent osteonecrosis of the femoral head (ONFH) in patients with systemic lupus erythematosus (SLE). Seventy-eight patients with SLE were selected on the basis of having been newly diagnosed and requiring high-dose prednisolone, including pulse therapy with methylprednisolone, as the initial treatment. All the patients initially underwent MRI at 3 months after the start of corticosteroid treatment to detect any early changes in the femoral head. These examinations were then performed again 3 months later. Laboratory parameters were evaluated at the start of steroid treatment and at 1 month thereafter. By 3 months after the start of corticosteroid treatment, silent ONFH was diagnosed by MRI in 21 patients (26.9 %), being bilateral in 11 patients and unilateral in 10. The occurrence of silent ONFH was not related to SLE disease activity index, serological activity, or renal function; it was also unrelated to body mass index (BMI), body surface area (BSA), and the initial dose of prednisolone per unit body weight. However, the total cholesterol level at 4 weeks after the start of steroid treatment tended to be higher in patients with silent ONFH. Patients with a higher triglyceride level showed a significantly higher frequency of silent ONFH both before (p = 0.002) and 4 weeks after (p = 0.036) steroid initiation.
A high triglyceride level is an important risk factor for silent ONFH in patients with SLE, and large-scale epidemiologic surveys of such early events are needed in this patient population.
Similar content being viewed by others
References
Abeles M, Urman JD, Rothfield NF (1978) Aseptic necrosis of bone in systemic lupus erythematosus. Relationship to corticosteroid therapy. Arch Intern Med 138:750–754
Koo KH, Kim R (1995) Quantifying the extent of osteonecrosis of the femoral head. A new method using MRI. J Bone Joint Surg Br 77:875–880
Landmann J, Renner N, Gächter A, Thiel G, Harder F (1978) Cyclosporin A and osteonecrosis of the femoral head. J Bone Joint Surg Am 69:1226–1228
Mont MA, Hungerford DS (1995) Non-traumatic avascular necrosis of the femoral head. J Bone Joint Surg Am 77:459–474
Moskal JT, Topping RE, Franklin LL (1997) Hypercholesterolemia: an association with osteonecrosis of the femoral head. Am J Orthop 26:609–612
Oinuma K, Harada Y, Nawata Y, Kobayashi K, Abe I, Kamikawa K, Moriya H (2000) Sustained hemostatic abnormality in patients with steroid-induced osteonecrosis in the early period after high-dose corticosteroid therapy. J Orthop Sci 5:374–379
Ichiseki T, Matsumoto T, Nishino M, Kaneuji A, Katsuda S (2004) Oxidative stress and vascular permeability in steroid-induced osteonecrosis model. J Orthop Sci 9:509–515
Iuchi T, Akaike M, Mitsui T, Ohshima Y, Shintani Y, Azuma H, Matsumoto T (2003) Glucocorticoid excess induces superoxide production in vascular endothelial cells and elicits vascular endothelial dysfunction. Circ Res 92:81–87
Bombardier C, Gladman DD, Urowitz MB, Carton D, Chang CH (1992) Derivation of the SLEDAI. A disease activity index for lupus patients. The committee on prognosis studies in SLE. Arthritis Rheum 35:630–640
Imai E, Horio M, Nitta K, Yamagata K, Iseki K, Tsukamoto Y, Ito S, Makino H, Hishida A, Matsuo S (2007) Modification of the modification of diet in renal disease (MDRD) study equation for Japan. Am J Kidney Dis 50:927–937
DuBois D, DuBois EF (1989) A formula to estimate the approximate surface area if height and weight be known. Arch Intern Med 17:863–871
Nagasawa K, Tada Y, Koarada S, Horiuchi T, Tsukamoto H, Murai K, Ueda A, Yoshizawa S, Ohta A (2005) Very early development of steroid-associated osteonecrosis of femoral head in systemic lupus erythematosus: prospective study by MRI. Lupus 14:385–390
Seleznick MJ, Silveira LH, Espinoza LR (1991) Avascular necrosis associated with anticardiolipin antibodies. J Rheumatol 18:1416–1417
Calvo-Alén J, McGwin G, Toloza S, Fernández M, Roseman JM, Bastian HM, Cepeda EJ, González EB, Baethge BA, Fessler BJ, Vilá LM, Reveille JD, Alarcón GS, LUMINA Study Group (2006) Systemic lupus erythematosus in a multiethnic US cohort (LUMINA): XXIV. Cytotoxic treatment is an additional risk factor for the development of symptomatic osteonecrosis in lupus patients: results of a nested matched case-control study. Ann Rheum Dis 65:785–790
Takahashi S, Fukushima W, Kubo T, Iwamoto Y, Hirota Y, Nakamura H (2012) Pronounced risk of nontraumatic osteonecrosis of the femoral head among cigarette smokers who have never used oral corticosteroids: a multicenter case-control study in Japan. J Orthop Sci 17:730–736
Wang GJ, Cui Q, Balian G (2000) The pathogenesis and prevention of steroid-induced osteonecrosis. Clin Orthop Relat Res 370:295–310
Nishida K, Yamamoto T, Motomura G, Jingushi S, Iwamoto Y (2008) Pitavastatin may reduce risk of steroid-induced osteonecrosis in rabbits. Clin Orthop Relat Res 466:1054–1058
Sekiya F, Yamaji K, Yang K, Tsuda H, Takasaki Y (2010) Investigation of occurrence of osteonecrosis of the femoral head after increasing corticosteroids in patients with recurring systemic lupus erythematosus. Rheumatol Int 30:1587–1593
Fesslar BJ, Boumpas DT (1995) Severe major organ involvement in systemic lupus erythematosus. Diagnosis and management. Rheum Sis Clin North Am 21:81–98
Noda H, Iso H, Saito I, Konishi M, Inoue M, Tsugane S, JPHC Study Group (2009) The impact of the metabolic syndrome and its components on the incidence of ischemic heart disease and stroke: the Japan public health center-based study. Hypertens Res 32:289–298
Patel A, Barzi F, Jamrozik K, Lam TH, Ueshima H, Whitlock G, Woodward M, Asia Pacific Cohort Studies Collaboration (2004) Serum triglycerides as a risk factor for cardiovascular diseases in the Asia-Pacific region. Circulation 110:2678–2686
Sarwar N, Danesh J, Eiriksdottir G, Sigurdsson G, Wareham N, Bingham S, Boekholdt SM, Khaw KT, Gudnason V (2007) Triglycerides and the risk of coronary heart disease: 10,158 incident cases among 262,525 participants in 29 Western prospective studies. Circulation 115:450–458
Acknowledgments
This study was supported by a research grant from the Research Committee on Idiopathic Osteonecrosis of the Femoral Head of the Ministry of Health, Labour, and Welfare of Japan.
Disclosures
None.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Kuroda, T., Tanabe, N., Wakamatsu, A. et al. High triglyceride is a risk factor for silent osteonecrosis of the femoral head in systemic lupus erythematosus. Clin Rheumatol 34, 2071–2077 (2015). https://doi.org/10.1007/s10067-015-3075-y
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10067-015-3075-y